Stifel Nicolaus analyst Derek Archila maintained a Buy rating on Argenx Se (ARGX) on January 4 and set a price target of $318.00. The company’s shares closed last Wednesday at $305.36, close to its 52-week high of $312.06.
According to TipRanks.com, Archila is a 4-star analyst with an average return of 13.3% and a 51.3% success rate. Archila covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Madrigal Pharmaceuticals, and Apellis Pharmaceuticals.
Currently, the analyst consensus on Argenx Se is a Moderate Buy with an average price target of $297.64, which is a 3.9% upside from current levels. In a report issued on January 7, JMP Securities also maintained a Buy rating on the stock with a $307.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $312.06 and a one-year low of $103.75. Currently, Argenx Se has an average volume of 150.3K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
argenx SE is a clinical-stage biotechnology company, which engages in the development of antibody-based therapies for the treatment of autoimmune diseases and cancer. Its products include ARGX-113 for the treatment of autoimmune disease myasthenia gravis and ARGX-110 for the treatment of hematological cancer acute myeloid leukemia. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren on April 25, 2008 and is headquartered in Breda, the Netherlands.
